EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France

Giulia Tammam iD, Abderhmane Slioui iD, Diane Friedman, Blandine Acket, Michele Cavalli, Saskia Bresch, Emmeline Lagrange, Guilhem Sole, Jean-Baptiste Noury, Luce Barbat Du Closel, Clémence Marois iD, Aleksandra Nadaj Pakleza und 19 weitere

Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1313-1325

DOI: 10.1177/22143602261437792 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 29.03.2026. Verfasst von Giulia Tammam und 30 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for Neuromuscular Disorders, Peripheral Nervous System and Muscle Department, Nice University Hospital, Pasteur 2 Hospital, NICE, Fr…. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centre Hospitalier Universitaire de Nice.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effectiveness and safety of zilucoplan in the real-world treatment setting in France.

Methods

This retrospective cohort study evaluated patients with generalized anti-AChR myasthenia gravis (MG) failing current therapy enrolled in the French early access program (EAP) for zilucoplan. Patients were evaluated at enrollment and at Months 1, 3 and 6 with the MG-ADL score, the Myasthenic Muscle Score (MMS-Garches), and the MG-quality of life questionnaire (MG-QoL15r). MG crises and on-treatment adverse events were documented. MG medication use was compared between the six months before and after enrollment.

Results

Forty-eight patients were enrolled and treated with zilucoplan (mean age: 56.2 years; 50.9% men). Thirty patients achieved six months follow-up before the EAP ended. Three patients discontinued zilucoplan due to lack of efficacy. Mean MG-ADL score decreased from 7.4 ± 4.4 to M0 to 2.5 ± 2.7 at M6 ( p < 0.0001). 9/43 patients achieved minimal symptom expression at M3 and 12/30 at M6. Mean MMS-Garches score was 67.5 ± 20.0 at M0 and 87.5 ± 13.2 at M6 ( p < 0.0001). Mean MG-QoL15r score was 18.2 ± 8.6 at M0 and 8.7 ± 8.3 at M6 ( p = 0.0156). 15 patients experienced adverse events, leading to discontinuation in four cases. The mean oral corticosteroid dose decreased from 28.8 ± 11.8 mg to 17.9 ± 11.8 ( p = 0.001). Six patients experienced MG crises on treatment, compared to 22 in the six months preceding enrollment. treatment.

Discussion

Following initiation of zilucoplan treatment, we observed an improvement in MG symptoms and a reduction in MG crises and in exposure to oral corticosteroids. Overall, zilucoplan was well-tolerated with no major adverse events reported. Trial registration information The study was registered in the clinicaltrials.gov trial registry under the number NCT06815133 ( https://clinicaltrials.gov/study/NCT06815133 ) on February 4 th , 2025.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAdultAgedFemaleHumansMaleMiddle AgedFranceQuality of LifeReceptors, CholinergicRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

corticosteroidseffectivenessmyasthenia gravisquality of lifereal-world evidencesafetyzilucoplan

Substanzen

Receptors, Cholinergic

Autor:innen und Institutionen

  • Reference Center for Neuromuscular Disorders, Peripheral Nervous System and Muscle Department, Nice University Hospital, Pasteur 2 Hospital, NICE, France.
  • Department of Intensive Care, Raymond Poincaré Hospital, APHP University Versailles Saint Quentin-University Paris Saclay, PARIS, France.
  • Department of Neurology, Toulouse University Hospital, TOULOUSE, France.
  • Reference Center for Neuromuscular Disorders, Grenoble University Hospital, GRENOBLE, France.
  • Reference Center for Neuromuscular Disorders, FILNEMUS, EURO-NMD, Neurology and Neuromuscular Diseases Department, Pellegrin Hospital, Bordeaux University Hospitals, BORDEAUX, France.
  • INSERM Lymphocytes B, Autommunity and Immunotherapy UMR1227, University of Western Brittany, BREST, France.

ORCID-Profile: Giulia Tammam, Abderhmane Slioui, Clémence Marois, Céline Tard, Djillali Annane, Simon Frachet, Julien Praline, Stéphane Beltran, Sabrina Sacconi

Förderung

  • Centre Hospitalier Universitaire de Nice

Zitieren

APA

Tammam, G., Slioui, A., Friedman, D., Acket, B., Cavalli, M., Bresch, S., Lagrange, E., Sole, G., Noury, J. B., Barbat Du Closel, L., Marois, C., Pakleza, A. N., Tard, C., Salort-Campana, E., Merle, P. E., Annane, D., Attarian, S., Duval, F., Frachet, S., …, & Sacconi, S. (2026). Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France. Journal of Neuromuscular Diseases, 13(6), 1313-1325. https://doi.org/10.1177/22143602261437792

Vancouver

Tammam G, Slioui A, Friedman D, Acket B, Cavalli M, Bresch S, et al. Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France. Journal of Neuromuscular Diseases. 2026;13(6):1313-1325. doi:10.1177/22143602261437792

BibTeX
@article{Tammam2026,
  author = {Tammam, Giulia and Slioui, Abderhmane and Friedman, Diane and Acket, Blandine and Cavalli, Michele and Bresch, Saskia and Lagrange, Emmeline and Sole, Guilhem and Noury, Jean-Baptiste and Barbat Du Closel, Luce and Marois, Clémence and Pakleza, Aleksandra Nadaj and Tard, Céline and Salort-Campana, Emmanuelle and Merle, Philippe-Edouard and Annane, Djillali and Attarian, Shahram and Duval, Fanny and Frachet, Simon and Svahn, Juliette and Pegat, Antoine and Bouhour, Françoise and Taieb, Guillaume and Praline, Julien and Puma, Angela and Fabry, Vincent and Villa, Luisa and Beltran, Stéphane and Behin, Anthony and Cintas, Pascal and Sacconi, Sabrina},
  title = {Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1313--1325},
  doi = {10.1177/22143602261437792}
}
Kostenlos starten →